The growth hormone response to hexarelin in patients with Prader-Willi syndrome

M. Cappa, G. Raguso, T. Palmiotto, A. Faedda, F. Gurreri, G. Neri, R. Deghenghi, S. Loche

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hexarelin (Hex) is a synthetic hexapeptide with potent GH-releasing activity in both animals and men. Aim of this study was to evaluate the GH response to a maximal dose of Hex and GH-releasing hormone (GHRH) in a group of patients with Prader-Willi syndrome (PWS). Seven patients (4 boys and 3 girls, age 2.4-14.2 yr) with PWS, 10 prepubertal obese children (7 boys and 3 girls, age 7.5-12.0 yr), and 24 prepubertal short normal children (11 boys and 13 girls, age 5.9-13 yr) with body weight within ± 10% of their ideal weight were studied. All subjects were tested on two occasions with GHRH 1-29 at the dose of 1 μg/Kg iv, and with Hex at the dose of 2 μg/Kg iv. In the PWS patients the GH response to GHRH (peak = 6.4 ± 2.0 μg/l, p <0.0001; AUC = 248 ± 70 μg min/l, p <0.0001) was significantly lower than that observed in the short normal children and similar to that observed in the obese children. In the PWS children the GH response to Hex (peak = 7.5 ± 1.6 μg/l; AUC = 309 ± 53) was similar to that observed after GHRH and significantly lower than that observed in the obese children (p <0.05). The results of this study show that PWS patients have a blunted GH response to the administration of a maximal dose of Hex. Whether these findings reflect a more severe pituitary GH deficiency in PWS than in obese children or a deranged hypothalamic regulation of GH secretion need further investigation.

Original languageEnglish
Pages (from-to)501-505
Number of pages5
JournalJournal of Endocrinological Investigation
Volume21
Issue number8
Publication statusPublished - Sep 1998

Fingerprint

Prader-Willi Syndrome
Growth Hormone
Hormones
Area Under Curve
hexarelin
Body Weight
Weights and Measures

Keywords

  • Growth hormone
  • Growth hormone releasing hormone
  • Hexarelin
  • Obesity
  • Prader-Willi

ASJC Scopus subject areas

  • Endocrinology

Cite this

Cappa, M., Raguso, G., Palmiotto, T., Faedda, A., Gurreri, F., Neri, G., ... Loche, S. (1998). The growth hormone response to hexarelin in patients with Prader-Willi syndrome. Journal of Endocrinological Investigation, 21(8), 501-505.

The growth hormone response to hexarelin in patients with Prader-Willi syndrome. / Cappa, M.; Raguso, G.; Palmiotto, T.; Faedda, A.; Gurreri, F.; Neri, G.; Deghenghi, R.; Loche, S.

In: Journal of Endocrinological Investigation, Vol. 21, No. 8, 09.1998, p. 501-505.

Research output: Contribution to journalArticle

Cappa, M, Raguso, G, Palmiotto, T, Faedda, A, Gurreri, F, Neri, G, Deghenghi, R & Loche, S 1998, 'The growth hormone response to hexarelin in patients with Prader-Willi syndrome', Journal of Endocrinological Investigation, vol. 21, no. 8, pp. 501-505.
Cappa M, Raguso G, Palmiotto T, Faedda A, Gurreri F, Neri G et al. The growth hormone response to hexarelin in patients with Prader-Willi syndrome. Journal of Endocrinological Investigation. 1998 Sep;21(8):501-505.
Cappa, M. ; Raguso, G. ; Palmiotto, T. ; Faedda, A. ; Gurreri, F. ; Neri, G. ; Deghenghi, R. ; Loche, S. / The growth hormone response to hexarelin in patients with Prader-Willi syndrome. In: Journal of Endocrinological Investigation. 1998 ; Vol. 21, No. 8. pp. 501-505.
@article{28073e9ed5ac499cab7109ba674831b8,
title = "The growth hormone response to hexarelin in patients with Prader-Willi syndrome",
abstract = "Hexarelin (Hex) is a synthetic hexapeptide with potent GH-releasing activity in both animals and men. Aim of this study was to evaluate the GH response to a maximal dose of Hex and GH-releasing hormone (GHRH) in a group of patients with Prader-Willi syndrome (PWS). Seven patients (4 boys and 3 girls, age 2.4-14.2 yr) with PWS, 10 prepubertal obese children (7 boys and 3 girls, age 7.5-12.0 yr), and 24 prepubertal short normal children (11 boys and 13 girls, age 5.9-13 yr) with body weight within ± 10{\%} of their ideal weight were studied. All subjects were tested on two occasions with GHRH 1-29 at the dose of 1 μg/Kg iv, and with Hex at the dose of 2 μg/Kg iv. In the PWS patients the GH response to GHRH (peak = 6.4 ± 2.0 μg/l, p <0.0001; AUC = 248 ± 70 μg min/l, p <0.0001) was significantly lower than that observed in the short normal children and similar to that observed in the obese children. In the PWS children the GH response to Hex (peak = 7.5 ± 1.6 μg/l; AUC = 309 ± 53) was similar to that observed after GHRH and significantly lower than that observed in the obese children (p <0.05). The results of this study show that PWS patients have a blunted GH response to the administration of a maximal dose of Hex. Whether these findings reflect a more severe pituitary GH deficiency in PWS than in obese children or a deranged hypothalamic regulation of GH secretion need further investigation.",
keywords = "Growth hormone, Growth hormone releasing hormone, Hexarelin, Obesity, Prader-Willi",
author = "M. Cappa and G. Raguso and T. Palmiotto and A. Faedda and F. Gurreri and G. Neri and R. Deghenghi and S. Loche",
year = "1998",
month = "9",
language = "English",
volume = "21",
pages = "501--505",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "8",

}

TY - JOUR

T1 - The growth hormone response to hexarelin in patients with Prader-Willi syndrome

AU - Cappa, M.

AU - Raguso, G.

AU - Palmiotto, T.

AU - Faedda, A.

AU - Gurreri, F.

AU - Neri, G.

AU - Deghenghi, R.

AU - Loche, S.

PY - 1998/9

Y1 - 1998/9

N2 - Hexarelin (Hex) is a synthetic hexapeptide with potent GH-releasing activity in both animals and men. Aim of this study was to evaluate the GH response to a maximal dose of Hex and GH-releasing hormone (GHRH) in a group of patients with Prader-Willi syndrome (PWS). Seven patients (4 boys and 3 girls, age 2.4-14.2 yr) with PWS, 10 prepubertal obese children (7 boys and 3 girls, age 7.5-12.0 yr), and 24 prepubertal short normal children (11 boys and 13 girls, age 5.9-13 yr) with body weight within ± 10% of their ideal weight were studied. All subjects were tested on two occasions with GHRH 1-29 at the dose of 1 μg/Kg iv, and with Hex at the dose of 2 μg/Kg iv. In the PWS patients the GH response to GHRH (peak = 6.4 ± 2.0 μg/l, p <0.0001; AUC = 248 ± 70 μg min/l, p <0.0001) was significantly lower than that observed in the short normal children and similar to that observed in the obese children. In the PWS children the GH response to Hex (peak = 7.5 ± 1.6 μg/l; AUC = 309 ± 53) was similar to that observed after GHRH and significantly lower than that observed in the obese children (p <0.05). The results of this study show that PWS patients have a blunted GH response to the administration of a maximal dose of Hex. Whether these findings reflect a more severe pituitary GH deficiency in PWS than in obese children or a deranged hypothalamic regulation of GH secretion need further investigation.

AB - Hexarelin (Hex) is a synthetic hexapeptide with potent GH-releasing activity in both animals and men. Aim of this study was to evaluate the GH response to a maximal dose of Hex and GH-releasing hormone (GHRH) in a group of patients with Prader-Willi syndrome (PWS). Seven patients (4 boys and 3 girls, age 2.4-14.2 yr) with PWS, 10 prepubertal obese children (7 boys and 3 girls, age 7.5-12.0 yr), and 24 prepubertal short normal children (11 boys and 13 girls, age 5.9-13 yr) with body weight within ± 10% of their ideal weight were studied. All subjects were tested on two occasions with GHRH 1-29 at the dose of 1 μg/Kg iv, and with Hex at the dose of 2 μg/Kg iv. In the PWS patients the GH response to GHRH (peak = 6.4 ± 2.0 μg/l, p <0.0001; AUC = 248 ± 70 μg min/l, p <0.0001) was significantly lower than that observed in the short normal children and similar to that observed in the obese children. In the PWS children the GH response to Hex (peak = 7.5 ± 1.6 μg/l; AUC = 309 ± 53) was similar to that observed after GHRH and significantly lower than that observed in the obese children (p <0.05). The results of this study show that PWS patients have a blunted GH response to the administration of a maximal dose of Hex. Whether these findings reflect a more severe pituitary GH deficiency in PWS than in obese children or a deranged hypothalamic regulation of GH secretion need further investigation.

KW - Growth hormone

KW - Growth hormone releasing hormone

KW - Hexarelin

KW - Obesity

KW - Prader-Willi

UR - http://www.scopus.com/inward/record.url?scp=0031661479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031661479&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 501

EP - 505

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 8

ER -